Ningbo Ziyuan Pharmaceuticals

Ningbo Ziyuan Pharmaceuticals is a clinical-stage biotechnology company based in Ningbo, China, specializing in the development of small molecule therapeutics for autoimmune and inflammatory diseases. The company's primary focus is the development of DZ2002 (Deoxyeritadenine methyl ester), a reversible S-adenosyl-L-homocysteine hydrolase (SAHH) inhibitor licensed from the Shanghai Institute of Materia Medica. DZ2002 is currently undergoing Phase 1 clinical evaluation for the treatment of psoriasis and has demonstrated potential in preclinical studies for other conditions, including lupus and dry eye disease. Ningbo Ziyuan leverages its expertise in chemical synthesis and immunology to advance its pipeline of targeted therapies.